Advances in Therapy

, Volume 29, Issue 10, pp 826–848 | Cite as

Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review

  • Stephen TooveyEmail author
  • Eric P. Prinssen
  • Craig R. Rayner
  • Bharat T. Thakrar
  • Regina Dutkowski
  • Annette Koerner
  • Tom Chu
  • Alexandra Sirzen-Zelenskaya
  • Markus Britschgi
  • Sudhir Bansod
  • Barbara Donner
Open Access


A 2008 review by our group concluded that the risk of neuropsychiatric adverse events (NPAEs) in influenza patients was not increased by oseltamivir exposure, and did not identify any mechanism by which oseltamivir or its metabolites could cause or worsen such events. The current article reviews new information on this topic. Between September 16, 2007 and May 15, 2010, 1,805 spontaneously-reported NPAEs were identified in 1,330 patients receiving oseltamivir: 767 (42.5%) from Japan, 296 (16.4%) from the USA, and 742 (41.1%) from other countries. NPAEs were more common in children: 1,072 (59.4%) events were in those aged ≤16 years. NPAEs often occurred within 48 h of treatment initiation (953 events; 52.8%). Nearly half of the events were serious in nature (838; 46.4%). The three largest categories of events were abnormal behavior (457 events, 25.3%), miscellaneous psychiatric events (370; 20.5%), and delusions/perceptual disturbances (316 events, 17.5%). A total of 1,545 events (85.6%) in eight different categories were considered to be delirium or delirium-like. Twenty-eight suicide-related events were reported. A US healthcare claims database analysis showed that the risk of NPAEs in 7,798 oseltamivir-treated patients was no higher than that in 10,411 patients not on antivirals, but a study on oseltamivir and abnormal behavior in Japan was less conclusive. NPAE frequency in oseltamivir-exposed Japanese and Taiwanese children with influenza was the same as in unexposed children. New analysis of the UK General Practice Research Database showed that the relative adjusted risk of NPAEs in influenza patients was 2.18-times higher than in the general population. Other epidemiology studies report frequent occurrence of encephalitis and similar disorders in influenza patients independently of oseltamivir exposure. The new data support the findings of the original assessment. Evidence suggests that influenza-related encephalopathies are caused by influenza-induced inflammatory responses, but more work is needed to confirm the underlying mechanisms.

Supplementary material is available on


Adverse events Central nervous system Influenza Neuropsychiatric Oseltamivir Safety Tolerability 

Supplementary material

12325_2012_50_MOESM1_ESM.pdf (715 kb)
Supplementary material, approximately 715 KB.


  1. 1.
    Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31:1097–114.PubMedGoogle Scholar
  2. 2.
    Kasai T, Togashi T, Morishima T. Encephalopathy associated with influenza epidemics. Lancet. 2000;355:1558–9.PubMedGoogle Scholar
  3. 3.
    Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002;35:512–7.PubMedGoogle Scholar
  4. 4.
    Okabe N, Yamashita K, Taniguchi K, Inouye S. Influenza surveillance system of Japan and acute encephalitis and encephalopathy in the influenza season. Pediatr Int. 2000;42:187–91.PubMedGoogle Scholar
  5. 5.
    Food and Drug Administration (FDA). Meeting of the FDA Pediatric Advisory Committee. November 16, 2006. Available at: Accessed Sep 10 2012
  6. 6.
    Donner B, Bader-Weder S, Schwarz R, Peng MM, Smith JR, Niranjan V. Safety profile of oseltamivir during the 2009 influenza pandemic. Pharmacoepidemiol Drug Saf. 2011;20:532–43.PubMedGoogle Scholar
  7. 7.
    Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract. 2009;63:596–605.PubMedGoogle Scholar
  8. 8.
    Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21:79–89.PubMedGoogle Scholar
  9. 9.
    Hirota Y. Survey research on the emergence of influenza-associated symptoms. 2007/2008 research subteam report. 2009. Tokyo: MHLW Scientific Research Fund.Google Scholar
  10. 10.
    Yorifuji T, Suzuki E, Tsuda T. Oseltamivir and abnormal behaviors: true or not? Epidemiology. 2009;20:619–21.PubMedGoogle Scholar
  11. 11.
    Peng MM, Robinson NJ. Oseltamivir and abnormal behavior. Epidemiology. 2010;21:915–6.PubMedGoogle Scholar
  12. 12.
    Kimberlin DW, Shalabi M, Abzug MJ, et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J. 2010;29:195–8.PubMedGoogle Scholar
  13. 13.
    Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationship. Int J Risk Saf Med. 2008;20:5–36.Google Scholar
  14. 14.
    Huang YC, Li WC, Tsao KC, et al. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J. 2009;28:647–8.PubMedGoogle Scholar
  15. 15.
    Tanabe T, Hara K, Nakajima M, Shimakawa S, Tamai H. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. Brain Dev. 2010;32:440–4.PubMedGoogle Scholar
  16. 16.
    Takanashi J, Tada H, Kuroki H, Barkovich AJ. Delirious behavior in influenza is associated with a reversible splenial lesion. Brain Dev. 2009;31:423–6.PubMedGoogle Scholar
  17. 17.
    Baltagi SA, Shoykhet M, Felmet K, Kochanek PM, Bell MJ. Neurological sequelae of 2009 influenza A (H1N1) in children: a case series observed during a pandemic. Pediatr Crit Care Med. 2010;11:179–84.PubMedGoogle Scholar
  18. 18.
    Rellosa N, Bloch KC, Shane AL, Debiasi RL. Neurologic manifestations of pediatric novel H1N1 influenza infection. Pediatr Infect Dis J. 2011;30:165–7.PubMedGoogle Scholar
  19. 19.
    Tan K, Prerna A, Leo YS. Surveillance of H1N1-related neurological complications. Lancet Neurol. 2010;9:142–3.PubMedGoogle Scholar
  20. 20.
    Wiwanitkit V. Swine flu encephalitis: a comment on the first case in Thailand. J Neurol Sci. 2009;26:518–9.Google Scholar
  21. 21.
    Calitri C, Gabiano C, Garazzino S, et al. Clinical features of hospitalised children with 2009 H1N1 influenza virus infection. Eur J Pediatr. 2010;169:1511–5.PubMedGoogle Scholar
  22. 22.
    Centers for Disease Control and Prevention (CDC). Neurologic complications associated with novel influenza A (H1N1) virus infection in children — Dallas, Texas, May 2009. MMWR Morb Mortal Wkly Rep. 2009;58:773–8.Google Scholar
  23. 23.
    Chen YC, Lo CP, Chang TP. Novel influenza A (H1N1)-associated encephalopathy/encephalitis with severe neurological sequelae and unique image features — A case report. J Neurol Sci. 2010;298:110–3.PubMedGoogle Scholar
  24. 24.
    Citerio G, Sala F, Patruno A, et al. Influenza A (H1N1) encephalitis with severe intracranial hypertension. Minerva Anestesiol. 2010;76:459–62.PubMedGoogle Scholar
  25. 25.
    German-Diaz M, Pavo-Garcia R, Diaz-Diaz J, Giangaspro-Corradi E, Negreira-Cepeda S. Adolescent with neuropsychiatric symptoms associated with novel influenza A (H1N1) virus infection. Pediatr Infect Dis J. 2010;29:570–1.PubMedGoogle Scholar
  26. 26.
    Gonzalez BE, Brust DG. Novel influenza A (H1N1) presenting as an acute febrile encephalopathy in a mother and daughter. Clin Infect Dis. 2009;49:1966–7.PubMedGoogle Scholar
  27. 27.
    Haktanir A. MR imaging in novel influenza A(H1N1)-associated meningoencephalitis. AJNR Am J Neuroradiol. 2010;31:394–5.PubMedGoogle Scholar
  28. 28.
    Kedia S, Stroud B, Parsons J, et al. Pediatric neurological complications of 2009 pandemic influenza A (H1N1). Arch Neurol. 2011;68:455–62.PubMedGoogle Scholar
  29. 29.
    Kwong KL, Hiu H, Hui CM, Que TL. A tragic case of flu. HK J Paediatr. 2007;12:199–201.Google Scholar
  30. 30.
    Lee N, Wong CK, Chan PK, et al. Acute encephalopathy associated with influenza A infection in adults. Emerg Infect Dis. 2010;16:139–42.PubMedGoogle Scholar
  31. 31.
    Li X, Du Y. Neurologic complications associated with novel influenza A (H1N1) virus infection in Nanchong, Chengdu, November 2009. J Exp Clin Med. 2010;2:254–6.Google Scholar
  32. 32.
    Mariotti P, Iorio R, Frisullo G, et al. Acute necrotizing encephalopathy during novel influenza A (H1N1) virus infection. Ann Neurol. 2010;68:111–4.PubMedGoogle Scholar
  33. 33.
    Martin A, Reade EP. Acute necrotizing encephalopathy progressing to brain death in a pediatric patient with novel influenza A (H1N1) infection. Clin Infect Dis. 2010;50:e50–e52.PubMedGoogle Scholar
  34. 34.
    Noriega LM, Verdugo RJ, Araos R, et al. Pandemic influenza A (H1N1) 2009 with neurological manifestations, a case series. Influenza Other Respi Viruses. 2010;4:117–20.PubMedGoogle Scholar
  35. 35.
    O’Leary MF, Chappell JD, Stratton CW, et al. Complex febrile seizures followed by complete recovery in an infant with high-titer 2009 pandemic influenza A (H1N1) virus infection. J Clin Microbiol. 2010;48:3803–5.PubMedGoogle Scholar
  36. 36.
    Ormitti F, Ventura E, Summa A, Picetti E, Crisi G. Acute necrotizing encephalopathy in a child during the 2009 influenza A(H1N1) pandemia: MR imaging in diagnosis and follow-up. AJNR Am J Neuroradiol. 2010;31:396–400.PubMedGoogle Scholar
  37. 37.
    Samuel N, Attias O, Tatour S, Brik R. Novel influenza A (H1N1) and acute encephalitis in a child. Isr Med Assoc J. 2010;12:446–7.PubMedGoogle Scholar
  38. 38.
    Tada H, Takanashi JI, Terada H, Tajima K. Severe form of acute influenza encephalopathy with biphasic seizures and late reduced diffusion. Neuropediatrics. 2008;39:134–6.PubMedGoogle Scholar
  39. 39.
    Webster RI, Hazelton B, Suleiman J, et al. Severe encephalopathy with swine origin influenza A H1N1 infection in childhood: case reports. Neurology. 2010;74:1077–8.PubMedGoogle Scholar
  40. 40.
    Yamashita S, Kouzaki Y, Kawano R, Tokunaga M, Uchino M. Acute ophthalmoparesis accompanied with influenza A infection. Intern Med. 2008;47:1627–9.PubMedGoogle Scholar
  41. 41.
    Yildizdas D, Kendirli T, Arslankoylu AE, et al. Neurological complications of pandemic influenza (H1N1) in children. Eur J Pediatr. 2011;170:779–88.PubMedGoogle Scholar
  42. 42.
    Akins PT, Belko J, Uyeki TM, et al. H1N1 encephalitis with malignant edema and review of neurologic complications from influenza. Neurocrit Care. 2010;13:396–406.PubMedGoogle Scholar
  43. 43.
    Choi SY, Jang SH, Kim JO, et al. Novel swine-origin influenza A (H1N1) viral encephalitis. Yonsei Med J. 2010;51:291–2.PubMedGoogle Scholar
  44. 44.
    Costiniuk CT, Le SN, Sell E, et al. Miller Fisher syndrome in a toddler with influenza A (pH1N1) infection. J Child Neurol. 2011;26:385–8.PubMedGoogle Scholar
  45. 45.
    Gadoth A, Aizenstein O, Mosek A. Influenza A/H1N1 encephalitis. Neurology. 2010;75:666–7.PubMedGoogle Scholar
  46. 46.
    Kimura E, Okamoto S, Uchida Y, et al. A reversible lesion of the corpus callosum splenium with adult influenza-associated encephalitis/encephalopathy: a case report. J Med Case Reports. 2008;2:220.Google Scholar
  47. 47.
    Sanchez-Torrent L, Trivino-Rodriguez M, Suero-Toledano P, et al. Novel influenza A (H1N1) encephalitis in a 3-month-old infant. Infection. 2010;38:227–9.PubMedGoogle Scholar
  48. 48.
    Fugate JE, Lam EM, Rabinstein AA, Wijdicks EF. Acute hemorrhagic leukoencephalitis and hypoxic brain injury associated with H1N1 influenza. Arch Neurol. 2010;67:756–8.PubMedGoogle Scholar
  49. 49.
    Gonzalez-Duarte A, Magana ZL, Cantu BC, Garcia-Ramos G. Hypothalamic abnormalities and Parkinsonism associated with H1N1 influenza infection. J Neuroinflammation. 2010;7:47.PubMedGoogle Scholar
  50. 50.
    Data on file. Basel: Roche; 2010.Google Scholar
  51. 51.
    Okabe N. Research on Abnormal Behaviour Accompanying Influenza — Report of the 2008–2009 season. Available at: Accessed 23 Sep 2012
  52. 52.
    Fowler A, Stodberg T, Eriksson M, Wickstrom R. Childhood encephalitis in Sweden: etiology, clinical presentation and outcome. Eur J Paediatr Neurol. 2008;12:484–90.PubMedGoogle Scholar
  53. 53.
    Hjalmarsson A, Blomqvist P, Brytting M, Linde A, Skoldenberg B. Encephalitis after influenza in Sweden 1987-1998: a rare complication of a common infection. Eur Neurol. 2009;61:289–94.PubMedGoogle Scholar
  54. 54.
    Amin R, Ford-Jones E, Richardson SE, et al. Acute childhood encephalitis and encephalopathy associated with influenza: a prospective 11-year review. Pediatr Infect Dis J. 2008;27:390–5.PubMedGoogle Scholar
  55. 55.
    Ekstrand JJ, Herbener A, Rawlings J, et al. Heightened neurologic complications in children with pandemic H1N1 influenza. Ann Neurol. 2010;68:762–6.PubMedGoogle Scholar
  56. 56.
    Fukumoto Y, Okumura A, Hayakawa F, et al. Serum levels of cytokines and EEG findings in children with influenza associated with mild neurological complications. Brain Dev. 2007;29:425–30.PubMedGoogle Scholar
  57. 57.
    Li WC, Shih SR, Huang YC, et al. Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. J Clin Virol. 2008;42:45–51.PubMedGoogle Scholar
  58. 58.
    Chung B, Wong V. Relationship between five common viruses and febrile seizure in children. Arch Dis Child. 2007;92:593.Google Scholar
  59. 59.
    Chung BH, Tsang AM, Wong VC. Neurologic complications in children hospitalized with influenza: comparison between USA and Hong Kong. J Pediatr. 2007;151:e17–8.PubMedGoogle Scholar
  60. 60.
    Kwong KL, Lung D, Wong SN, Que TL, Kwong NS. Influenza-related hospitalisations in children. J Paediatr Child Health. 2009;45:660–4.PubMedGoogle Scholar
  61. 61.
    Hon KL, Leung E, Tang J, et al. Premorbid factors and outcome associated with respiratory virus infections in a pediatric intensive care unit. Pediatr Pulmonol. 2008;43:275–80.PubMedGoogle Scholar
  62. 62.
    Louie JK, Gavali S, Acosta M, et al. Children hospitalized with 2009 novel influenza A(H1N1) in California. Arch Pediatr Adolesc Med. 2010;164:1023–31.PubMedGoogle Scholar
  63. 63.
    Parakh A, Kumar A, Kumar V, Dutta AK, Khare S. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1): an experience from a tertiary care center in North India. Indian J Pediatr. 2010;77:981–5.PubMedGoogle Scholar
  64. 64.
    Stein M, Tasher D, Glikman D, et al. Hospitalization of children with influenza A(H1N1) virus in Israel during the 2009 outbreak in Israel: a multicenter survey. Arch Pediatr Adolesc Med. 2010;164:1015–22.PubMedGoogle Scholar
  65. 65.
    Zheng Y, He Y, Deng J, et al. Hospitalized children with 2009 influenza a (H1N1) infection in Shenzhen, China, November–December 2009. Pediatr Pulmonol. 2010; Oct 20. [Epub ahead of print.]Google Scholar
  66. 66.
    Shin SY, Kim JH, Kim HS, et al. Clinical characteristics of Korean pediatric patients critically ill with influenza A (H1N1) virus. Pediatr Pulmonol. 2010;45:1014–20.PubMedGoogle Scholar
  67. 67.
    Zhao C, Gan Y, Sun J. Radiographic study of severe Influenza-A (H1N1) disease in children. Eur J Radiol 2011;79:447–51.PubMedGoogle Scholar
  68. 68.
    Wada T, Morishima T, Okumura A, et al. Differences in clinical manifestations of influenza-associated encephalopathy by age. Microbiol Immunol. 2009;53:83–8.PubMedGoogle Scholar
  69. 69.
    Nagao T, Morishima T, Kimura H, et al. Prognostic factors in influenza-associated encephalopathy. Pediatr Infect Dis J. 2008;27:384–9.PubMedGoogle Scholar
  70. 70.
    Wang CC, Chen PY, Wang JD, et al. Clinical and laboratory analysis of influenza B infection in children in Taichung, Taiwan during the 2006–2007 flu season. Pediatr Neonatol. 2009;50:54–8.PubMedGoogle Scholar
  71. 71.
    Terada K, Kawai Y, Monju A, Wakabayashi T, Ouchi K. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J. 2008;27:88–9.PubMedGoogle Scholar
  72. 72.
    Takayanagi M, Umehara N, Watanabe H, et al. Acute encephalopathy associated with influenza C virus infection. Pediatr Infect Dis J. 2009;28:554.PubMedGoogle Scholar
  73. 73.
    Okumura A, Abe S, Kidokoro H, Mizuguchi M. Acute necrotizing encephalopathy: a comparison between influenza and non-influenza cases. Microbiol Immunol. 2009;53:277–80.PubMedGoogle Scholar
  74. 74.
    Gika AD, Rich P, Gupta S, Neilson DE, Clarke A. Recurrent acute necrotizing encephalopathy following influenza A in a genetically predisposed family. Dev Med Child Neurol. 2010;52:99–102.PubMedGoogle Scholar
  75. 75.
    Lyon JB, Remigio C, Milligan T, Deline C. Acute necrotizing encephalopathy in a child with H1N1 influenza infection. Pediatr Radiol. 2010;40:200–5.PubMedGoogle Scholar
  76. 76.
    Ng WF, Chiu SC, Lam DS, et al. A 7-year-old boy dying of acute encephalopathy. Brain Pathol. 2010;20:261–4.PubMedGoogle Scholar
  77. 77.
    Troedson C, Gill D, Dale RC. Emergence of acute necrotising encephalopathy in Australia. J Paediatr Child Health. 2008;44:599–601.PubMedGoogle Scholar
  78. 78.
    Neilson DE, Adams MD, Orr CM, et al. Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet. 2009;84:44–51.PubMedGoogle Scholar
  79. 79.
    Bartynski WS, Upadhyaya AR, Petropoulou KA, Boardman JF. Influenza A encephalopathy, cerebral vasculopathy, and posterior reversible encephalopathy syndrome: combined occurrence in a 3-year-old child. AJNR Am J Neuroradiol. 2010;31:1443–6.PubMedGoogle Scholar
  80. 80.
    Bartynski WS, Upadhyaya AR, Boardman JF. Posterior reversible encephalopathy syndrome and cerebral vasculopathy associated with influenza A infection: report of a case and review of the literature. J Comput Assist Tomogr. 2009;33:917–22.PubMedGoogle Scholar
  81. 81.
    Henry J, Smeyne RJ, Jang H, Miller B, Okun MS. Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat Disord. 2010;16:566–71.PubMedGoogle Scholar
  82. 82.
    Toovey S, Jick SS, Meier CR. Parkinson’s disease or Parkinson symptoms following seasonal influenza. Influenza Other Respi Viruses. 2011;5:328–33.PubMedGoogle Scholar
  83. 83.
    Hoffmann G, Funk C, Fowler S, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009;53:4753–61.PubMedGoogle Scholar
  84. 84.
    Hatori A, Arai T, Yanamoto K, et al. Biodistribution and metabolism of the anti-influenza drug [11C] oseltamivir and its active metabolite [11C]Ro 64-0802 in mice. Nucl Med Biol. 2009;36:47–55.PubMedGoogle Scholar
  85. 85.
    Jhee SS, Yen M, Ereshefsky L, et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother. 2008;52:3687–93.PubMedGoogle Scholar
  86. 86.
    Ose A, Ito M, Kusuhara H, et al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009;37:315–21.PubMedGoogle Scholar
  87. 87.
    Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117:333–45.PubMedGoogle Scholar
  88. 88.
    Oshima S, Nemoto E, Kuramochi M, Saitoh Y, Kobayashi D. Penetration of oseltamivir and its active metabolite into the brain after lipopolysaccharide-induced inflammation in mice. J Pharm Pharmacol. 2009;61:1397–400.PubMedGoogle Scholar
  89. 89.
    Lindemann L, Jacobsen H, Schuhbauer D, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu®) and active metabolite. Eur J Pharmacol. 2010;628:6–10.PubMedGoogle Scholar
  90. 90.
    Izumi Y, Tokuda K, O’Dell KA, Zorumski CF, Narahashi T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett. 2007;426:54–8.PubMedGoogle Scholar
  91. 91.
    Knoflach F, Trube G, Buisson B, Steidl-Armougom E, Prinssen P, Lindemann L. Evaluation of pharmacological activities of oseltamivir on paired-pulse inhibition in the CA1 region of adult rat hippocampus. p. 822.18. Available at: Accessed Sep 10 2012
  92. 92.
    Usami A, Sasaki T, Satoh N, et al. Oseltamivir enhances hippocampal network synchronization. J Pharmacol Sci. 2008;106:659–62.PubMedGoogle Scholar
  93. 93.
    Satoh K, Nonaka R, Ogata A, Nakae D, Uehara S. Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain. Biol Pharm Bull. 2007;30:1816–8.PubMedGoogle Scholar
  94. 94.
    Data on file. Basel: Roche; 1998.Google Scholar
  95. 95.
    Izumi Y, Tokuda K, O’Dell K, Zorumski C, Narahashi T. Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants. Hum Exp Toxicol. 2008;27:911–7.PubMedGoogle Scholar
  96. 96.
    Uchimura N, Kuwahara H, Kumagai Y, et al. Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan. Basic Clin Pharmacol Toxicol. 2011;109:309–14.PubMedGoogle Scholar
  97. 97.
    Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective. Expert Opin Pharmacother. 2001;2:1671–83.PubMedGoogle Scholar
  98. 98.
    He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37:471–84.PubMedGoogle Scholar
  99. 99.
    Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2006;319:1477–84.PubMedGoogle Scholar
  100. 100.
    Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos. 2009;37:264–7.PubMedGoogle Scholar
  101. 101.
    Yang D, Pearce RE, Wang X, et al. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol. 2009;77:238–47.PubMedGoogle Scholar
  102. 102.
    Zhu HJ, Appel DI, Jiang Y, Markowitz JS. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos. 2009;37:1819–25.PubMedGoogle Scholar
  103. 103.
    Oo C, Barrett J, Hill G, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs. 2001;3:229–36.PubMedGoogle Scholar
  104. 104.
    Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis. 2010;202:563–6.PubMedGoogle Scholar
  105. 105.
    Aiba H, Mochizuki M, Kimura M, Hojo H. Predictive value of serum interleukin-6 level in influenza virus-associated encephalopathy. Neurology. 2001;57:295–9.PubMedGoogle Scholar
  106. 106.
    Ichiyama T, Isumi H, Ozawa H, et al. Cerebrospinal fluid and serum levels of cytokines and soluble tumor necrosis factor receptor in influenza virus-associated encephalopathy. Scand J Infect Dis. 2003;35:59–61.PubMedGoogle Scholar
  107. 107.
    Cisse Y, Wang S, Inoue I, Kido H. Rat model of influenza-associated encephalopathy (IAE): studies of electroencephalogram (EEG) in vivo. Neuroscience. 2010;165:1127–37.PubMedGoogle Scholar
  108. 108.
    Tanaka T, Sunden Y, Sakoda Y, et al. Lipopolysaccharide treatment and inoculation of influenza A virus results in influenza virus-associated encephalopathy-like changes in neonatal mice. J Neurovirol. 2010;16:125–32.PubMedGoogle Scholar
  109. 109.
    Riazi K, Galic MA, Kuzmiski JB, et al. Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci USA. 2008;105:17151–6.PubMedGoogle Scholar
  110. 110.
    Tsuge M, Yasui K, Ichiyawa T, et al. Increase of tumor necrosis factor-alpha in the blood induces early activation of matrix metalloproteinase-9 in the brain. Microbiol Immunol. 2010;54:417–24.PubMedGoogle Scholar
  111. 111.
    Serrats J, Schiltz JC, Garcia-Bueno B, et al. Dual roles for perivascular macrophages in immune-tobrain signaling. Neuron. 2010;65:94–106.PubMedGoogle Scholar
  112. 112.
    Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768–74.PubMedGoogle Scholar
  113. 113.
    Steinman L. Nuanced roles of cytokines in three major human brain disorders. J Clin Invest. 2008;118:3557–63.PubMedGoogle Scholar
  114. 114.
    Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.PubMedGoogle Scholar
  115. 115.
    Bentivoglio M, Kristensson K. Neural-immune interactions in disorders of sleep-wakefulness organization. Trends Neurosci. 2007;30:645–52.PubMedGoogle Scholar
  116. 116.
    Matsubara K, Kodera M, Nigami H, Yura K, Fukaya T. Reversible splenial lesion in influenza virus encephalopathy. Pediatr Neurol. 2007;37:431–4.PubMedGoogle Scholar
  117. 117.
    Fluss J, Ferey S, Menache-Starobinski C, et al. Mild influenza-associated encephalopathy/encephalitis with a reversible splenial lesion in a Caucasian child with additional cerebellar features. Eur J Paediatr Neurol. 2010;14:97–100.PubMedGoogle Scholar
  118. 118.
    Ganapathy S, Ey EH, Wolfson BJ, Khan N. Transient isolated lesion of the splenium associated with clinically mild influenza encephalitis. Pediatr Radiol. 2008;38:1243–5.PubMedGoogle Scholar
  119. 119.
    Iwata A, Matsubara K, Nigami H, Kamimura K, Fukaya T. Reversible splenial lesion associated with novel influenza A (H1N1) viral infection. Pediatr Neurol. 2010;42:447–50.PubMedGoogle Scholar
  120. 120.
    Tsuji M, Yoshida T, Miyakoshi C, Haruta T. Is a reversible splenial lesion a sign of encephalopathy? Pediatr Neurol. 2009;41:143–5.PubMedGoogle Scholar
  121. 121.
    Kotan D. Widespread subarachnoidal pneumocephalus development as a complication of influenza: a case report. Arch Med Sci. 2008;4:471–3.Google Scholar
  122. 122.
    Sumikoshi M, Hashimoto K, Kawasaki Y, et al. Human influenza virus infection and apoptosis induction in human vascular endothelial cells. J Med Virol. 2008;80:1072–8.PubMedGoogle Scholar
  123. 123.
    Wang G, Zhang J, Li W, et al. Apoptosis and proinflammatory cytokine responses of primary mouse microglia and astrocytes induced by human H1N1 and avian H5N1 influenza viruses. Cell Mol Immunol. 2008;5:113–20.PubMedGoogle Scholar
  124. 124.
    Kawada J, Kimura H, Ito Y, et al. Systemic cytokine responses in patients with influenza-associated encephalopathy. J Infect Dis. 2003;188:690–8.PubMedGoogle Scholar
  125. 125.
    van Zeijl JH, Bakkers J, Wilbrink B, et al. Influenza-associated encephalopathy: no evidence for neuroinvasion by influenza virus nor for reactivation of human herpesvirus 6 or 7. Clin Infect Dis. 2005;40:483–5.PubMedGoogle Scholar
  126. 126.
    Morishima T. Influenza-associated encephalopathy. No To Shinkei. 2006;58:561–9. In Japanese.PubMedGoogle Scholar
  127. 127.
    Shinohara M, Saitoh M, Takanashi JI, et al. Carnitine palmitoyl transferase II polymorphism is associated with multiple syndromes of acute encephalopathy with various infectious diseases. Brain Dev. 2011;33:512–7.PubMedGoogle Scholar
  128. 128.
    Yao D, Mizuguchi H, Yamaguchi M, et al. Thermal instability of compound variants of carnitine palmitoyltransferase II and impaired mitochondrial fuel utilization in influenza-associated encephalopathy. Hum Mutat. 2008;29:718–27.PubMedGoogle Scholar
  129. 129.
    Chen Y, Mizuguchi H, Yao D, et al. Thermolabile phenotype of carnitine palmitoyltransferase II variations as a predisposing factor for influenza-associated encephalopathy. FEBS Lett. 2005;579:2040–4.PubMedGoogle Scholar
  130. 130.
    Hosoya M, Kawasaki Y, Katayose M, et al. Prognostic predictive values of serum cytochrome c, cytokines, and other laboratory measurements in acute encephalopathy with multiple organ failure. Arch Dis Child. 2006;91:469–72.PubMedGoogle Scholar
  131. 131.
    Purevsuren J, Hasegawa Y, Kobayashi H, Endo M, Yamaguchi S. Urinary organic metabolite screening of children with influenza-associated encephalopathy for inborn errors of metabolism using GC/MS. Brain Dev. 2008;30:520–6.PubMedGoogle Scholar
  132. 132.
    Okamoto E. Incidence of injuries after influenza using health insurance claims. Jpn J Pharmacoepidemiol. 2009;21:50–1.Google Scholar
  133. 133.
    Berger JR, Houff SA. Neurological infections: the year of PML and influenza. Lancet Neurol. 2010;9:14–7.PubMedGoogle Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  • Stephen Toovey
    • 1
    Email author
  • Eric P. Prinssen
    • 1
  • Craig R. Rayner
    • 2
  • Bharat T. Thakrar
    • 1
  • Regina Dutkowski
    • 1
  • Annette Koerner
    • 1
  • Tom Chu
    • 3
  • Alexandra Sirzen-Zelenskaya
    • 1
  • Markus Britschgi
    • 1
  • Sudhir Bansod
    • 1
  • Barbara Donner
    • 1
  1. 1.F. Hoffmann-La Roche Ltd.BaselSwitzerland
  2. 2.Roche Products Pty. Ltd.MelbourneAustralia
  3. 3.Hoffmann-La Roche, Inc.NutleyUSA

Personalised recommendations